Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 2208 results found since Jan 2013.
Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials
CONCLUSIONS: In early breast cancer patients treated with adjuvant chemotherapy, baseline severe obesity was significantly linked to worse DFS and OS, and a BMI loss over 10% from baseline to post-adjuvant chemotherapy also negatively affected OS. Moreover, the prognostic role of BMI might differ between docetaxel-based and non-docetaxel-based groups.PMID:37429049 | DOI:10.1016/j.breast.2023.07.002
Source: Breast - July 10, 2023 Category: Cancer & Oncology Authors: Haizhu Chen Xiaoyan Qian Yunxia Tao Daquan Wang Ying Wang Yunfang Yu Herui Yao Source Type: research
Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer
CONCLUSION: An original SIS from the PRO-CTCAE for patients with breast cancer were verified the validity, reliability, and responsiveness. Further studies to improve and validate the SIS are needed.PMID:37422608 | DOI:10.1007/s12282-023-01480-3
Source: Breast Cancer - July 8, 2023 Category: Cancer & Oncology Authors: Yoko Suzuki Takayuki Iwamoto Maya Uno Minami Hatono Yukiko Kajiwara Yuko Takahashi Mariko Kochi Tadahiko Shien Yuichiro Kikawa Yukari Uemura Yasuhiro Hagiwara Seiichiro Yamamoto Naruto Taira Hiroyoshi Doihara Shinichi Toyooka Source Type: research
Surgical treatment strategies for pancreatic cancer with simultaneous liver metastasis
Conclusion: For highly selective patients with sLMPC who achieve partial response after receiving effective systemic treatment,the adoption of an aggressive surgical treatment strategy can significantly improve survival time;however, surgery dose not provide such survival benefits in patients who do not achieve partial response after systemic chemotherapy.PMID:37402686 | DOI:10.3760/cma.j.cn112139-20230329-00125
Source: Cancer Control - July 4, 2023 Category: Cancer & Oncology Authors: J Huang Z Y Yang R L Wei A T Y A H Atyah Y L Sun L Xu W Y Zhou Source Type: research
Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy
The objective response rate, defined as the sum of complete response (CR) and partial response (PR) rates, was 16.7%. The disease control rate, defined as the sum of CR, PR, and stable disease rates, was 50%. The frequency of adverse events during the second taxane was the same between the two groups (p > 0.999). Our report suggests that CAS patients could benefit from the second taxane treatment if the tumor is resistant to the first taxane.PMID:37400887 | DOI:10.1111/1346-8138.16873
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Satoru Yonekura Yuichiro Endo Hiroko Fujii Makiko Ishikawa Gyohei Egawa Kenji Kabashima Source Type: research
Cancer-associated fibroblast expression of glutamine fructose-6-phosphate aminotransferase 2 (GFPT2) is a prognostic marker in gastric cancer
In conclusion, GFPT2 plays an essential role in the function of CAFs in GC. It can be used as a biomarker to assess GC prognosis and immune infiltration.PMID:37395335 | DOI:10.1002/cjp2.333
Source: Clinical Colorectal Cancer - July 3, 2023 Category: Cancer & Oncology Authors: Shuo Yang Guoli Li Xin Yin Yufei Wang Xinju Jiang Xiulan Bian Tianyi Fang Shengjie Yin Lei Zhang Yingwei Xue Source Type: research
Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3 β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model
Bioorg Chem. 2023 Jun 25;139:106700. doi: 10.1016/j.bioorg.2023.106700. Online ahead of print.ABSTRACTGaleterone, 3β-(hydroxy)-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Gal, 1) and VNPP433-3β, 3β-(1H-imidazole-1-yl-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (2) are potent molecular glue degrader modulators of AR/AR-V7 and Mnk1/2-eIF4E signaling pathways, and are promising Phase 3 and Phase 1 drug candidates, respectively. Because appropriate salts can be utilized to create new chemical entities with enhanced aqueous solubility, in vivo pharmacokinetics, and enhanced in vitro and in vivo efficacies, the monohydro...
Source: Bioorganic Chemistry - July 1, 2023 Category: Chemistry Authors: Retheesh S Thankan Elizabeth Thomas Puranik Purushottamachar David J Weber Vincent C O Njar Source Type: research
Prostate Stereotactic Body Radiation Therapy Margins, Accelerated Partial Breast Irradiation Techniques, Total Neoadjuvant Therapy Local Control, Hyperfractionated Reirradiation, Hyaluronic Acid Rectal Spacer, and Concurrent Docetaxel for Head and Neck Cancer
Pract Radiat Oncol. 2023 Jul-Aug;13(4):267-272. doi: 10.1016/j.prro.2023.04.005.NO ABSTRACTPMID:37391233 | DOI:10.1016/j.prro.2023.04.005
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Laura Dover Caleb Dulaney Source Type: research
MiR-138-5p inhibits prostate cancer cell proliferation and chemoresistance by targeting APOBEC3B
In this study, we explored the role of APOBEC3B in PCa chemoresistance and the molecular mechanism of its dysregulated expression. Our results revealed that APOBEC3B was upregulated in PCa docetaxel-resistant cells, while its knockdown significantly repressed cell proliferation and docetaxel resistance of PCa cells. Bioinformatics and luciferase report analysis showed that miR-138-5p targeted APOBEC3B. In addition, miR-138-5p overexpression impeded cell proliferation and docetaxel resistance in PCa, while miR-138-5p inhibitors reversed this process. Further studies showed that upregulation of APOBEC3B expression in docetax...
Source: Translational Oncology - June 26, 2023 Category: Cancer & Oncology Authors: Lina Liu Yan Zhang Xi Hu Hui Zhang Chenyang Jiang Yan Guo Shundong Cang Source Type: research
Efficacy of cryotherapy on chemotherapy-induced peripheral neuropathy in patients with breast cancer: a propensity score-matched study
CONCLUSIONS: Cryotherapy relieves CIPN symptoms in breast cancer patients receiving carboplatin and paclitaxel chemotherapy. More thorough trials should be carried out to determine the best time limit and duration of cryotherapy.PMID:37363493 | PMC:PMC10289575 | DOI:10.1097/MS9.0000000000000906
Source: Hand Surgery - June 26, 2023 Category: Surgery Authors: Min Xu Fan Wang Xiaoli Zhu Zhaohua Hao Source Type: research
